c-Met Signaling as a Therapeutic Target in Head and Neck Cancer.

Area of Science:

• Oncology
• Cancer Biology
• Drug Development

Background:

• Head and neck squamous cell carcinoma (HNSCC), particularly HPV-negative types, frequently shows aberrant activation of epidermal growth factor receptor (EGFR) and c-Met oncogenes.
• While EGFR inhibitors like cetuximab are approved for HNSCC, no therapies targeting the c-Met pathway have reached regulatory approval.
• Aberrant c-Met signaling contributes to tumor progression and immune evasion in HNSCC.

Purpose of the Study:

• To review the rationale and current drug development strategies for targeting the c-Met pathway in HNSCC.
• To explore the potential of inhibiting c-Met or its ligand hepatocyte growth factor (HGF) in both tumor-intrinsic and tumor-extrinsic compartments.
• To highlight the unmet need for c-Met-targeted therapies in HPV-negative HNSCC.

Main Methods:

• Literature review of preclinical and clinical studies on c-Met signaling in HNSCC.
• Analysis of drug development pipelines for c-Met inhibitors and HGF-targeting agents.
• Discussion of the biological mechanisms underlying c-Met pathway activation and its role in HNSCC pathogenesis.

Main Results:

• EGFR activation has led to successful targeted therapy (cetuximab) in HNSCC.
• c-Met pathway dysregulation is common in HPV-negative HNSCC, driving proliferation, invasion, and metastasis.
• Targeting c-Met may overcome resistance mechanisms and modulate the immunosuppressive tumor microenvironment.

Conclusions:

• Inhibition of the c-Met pathway presents a promising therapeutic strategy for HPV-negative HNSCC.
• Further development of c-Met-targeting drugs is warranted to address the limitations of current treatments.
• Targeting c-Met could offer a dual benefit by directly inhibiting tumor growth and enhancing anti-tumor immunity.